Recent Development News: Q4 – 2016

Centrexion Therapeutics Announces Highly Statistically Significant Topline Results from Phase 2b Study of CNTX-4975 in Patients with Knee Osteoarthritis Pain

Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced positive topline data from its Phase 2b study of CNTX-4975 in patients … Continue reading

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

Global Financial Institution Extends Engagement with IPSA International

IPSA International (IPSA), a root9B Holdings (OTCQB: RTNBD) company and leading regulatory risk mitigation firm, today announced a contract extension with a global financial company. The new agreement is worth at least $875,000 and extends this relationship through the end … Continue reading

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

X4 Pharmaceuticals announces new data for lead candidate X4P-001 in renal cell carcinoma at EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer, today announced the presentation of preclinical data for X4P-001, the Company‚Äôs lead … Continue reading

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

Cerecor Reports Top-Line Data from CERC-301 Phase 2 Study for Major Depressive Disorder

Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced top-line clinical results from its major depressive disorder (MDD) Phase 2 clinical trial (Clin301-203) … Continue reading

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

Cerecor Announces Top-Line Results from CERC-501 Phase 2 Study for Nicotine Withdrawal

Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced top-line clinical results from its nicotine withdrawal Phase 2 clinical trial of CERC-501, an … Continue reading

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

root9B Technologies Names William L. Hoke Chief Financial Officer

root9B Technologies (OTCQB: RTNB), a leading provider of cybersecurity and regulatory risk mitigation, announced today that William L. Hoke, CPA has been appointed Chief Financial Officer, effective November 22, 2016.

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

ContraFect To Present at 28th Annual Piper Jaffray Health Conference

ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, announced today that Steven C. Gilman, PhD, the Company’s Chairman and CEO, will participate in … Continue reading

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

root9B Announces $790,000 Cyber Defense Contract Extension with Fortune 500 Company

root9B, a root9B Technologies Company (OTCQB: RTNB) and leading provider of advanced cyber defense operations, services, and products for commercial and government clients, announced today a contract extension with a Fortune 500 company. This new contract extends root9B’s HUNT Operations … Continue reading

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

root9B Remains #1 on the Cybersecurity 500 for 4th Consecutive Quarter

In response to remaining #1 on the Cybersecurity 500 for Q4 and the entirety of 2016, root9B’s Chief Executive Officer Eric Hipkins issued the following statement: “The root9B team is very excited and humbled to be listed yet again as … Continue reading

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

root9B Technologies Announces Third Quarter 2016 Financial Results

root9B Technologies, Inc. (OTCQB: RTNB) (“RTNB”) today announced financial results for the third quarter (“Q3″) and nine months (“YTD”) ended September 30, 2016, and reiterated its commitment to becoming a pure-play cybersecurity firm.

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301

ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that it has been granted a $2.1 million Technology/Therapeutic Development Award through the … Continue reading

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Morton’s Neuroma

Centrexion Therapeutics, a company focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced that the U.S. Food and Drug Administration (FDA) has … Continue reading

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off

Cerecor Inc. Reports Third Quarter 2016 Financial Results

Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing innovative drug candidates to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the third quarter ended September 30, 2016.

Posted in Recent Development News: Q4 - 2016, Recent Developments | Comments Off